Nanjing Hicin Pharmaceutical Co., Ltd.
Shenzhen Stock Exchange 300584.SZ
Nanjing Hicin Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) on January 27, 2025: 62.88
-
Nanjing Hicin Pharmaceutical Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 84.45 on October 08, 2024, which is 34.30% above the current Price to Earnings Ratio (P/E).
-
Nanjing Hicin Pharmaceutical Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 42.93 on February 07, 2024, which is -31.72% below the current Price to Earnings Ratio (P/E).
-
Nanjing Hicin Pharmaceutical Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 61.27.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
Don’t Miss A Beat
| CEO | Mr. Yuping Cao |
| IPO Date | Jan. 12, 2017 |
| Location | China |
| Headquarters | No.1 Hengfa Road |
| Employees | 553 |
| Sector | Healthcare |
| Industries | |
Nanjing Hicin Pharmaceutical Co., Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical preparations and synthetic chemicals in China. The company offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. It also provides technical transferring services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.
Past 5 years
StockViz Staff
February 4, 2025
Any question? Send us an email